Within the BC cohort, 3 patients had ER/PR positive (ER > 10% and/or PR > 10%) disease and 15 had triple-negative (ER < 10%, PR < 10%, HER2 negative by ASCO CAP guidelines) disease. This evidence concerns the gene ERBB2 and breast cancer.